Editorials

Defining Remission in Psoriatic Arthritis: Are We Getting Closer?  E.R. Soriano  ................................................................. 907
Participation in Leisure Activities among Canadian Children with Arthritis: A Wakeup Call for Physicians  C.M. LeBlanc  ................................................................. 909

Articles

A Study to Evaluate the Safety, Tolerability, and Efficacy of Brodalumab in Subjects with RA and an Inadequate Response to MTX  K. Pavelka, Y. Chon, R. Newmark, S.L. Lin, S. Baumgartner, N. Erondu  ................................................................. 912
Risk of Venous Thromboembolism after TKA in Patients with RA  M. Izumi, K. Migita, M. Nakamura, et al  ................................................................. 928
The Extent of Subclinical Atherosclerosis is Partially Predicted by the Inflammatory Load: A Prospective Study over 5 Years in Patients with RA and Matched Controls  A. Södergren, K. Karp, C. Bengtsson, B. Möller, S. Rantapää-Dahlqvist, S. Wållberg-Jonsson  ................................................................. 935
Upregulation of Thrombospondin 1 Expression in Synovial Tissues and Plasma of RA: Role of TGF-β1 toward Fibroblast-like Synovial Cells  T. Suzuki, N. Iwamoto, S. Yamasaki, et al  ................................................................. 943
Levels in Plasma of the Serine Proteases and Associated Proteins of the Lectin Pathway Are Altered in Patients with SLE  A. Trolldborg, S. Thiel, M.J. Laska, B. Deleuran, J.C. Jensenius, K. Stengaard-Pedersen  ................................................................. 948
Clinical Remission in Patients with Active PsA Treated with Adalimumab and Correlations in Joint and Skin Manifestations  F. Van den Bosch, A. Kavanaugh, M. Kron, H. Kupper, P.J. Mease  ................................................................. 952
Summary of Sensitivity and Specificity for PsA in a South African Cohort according to Classification Criteria  A.B. Maharaj, J. Govender, K. Maharaj, M. Rajkaran, P.P. Tak  ................................................................. 960

Low Levels of Serum Uric Acid Increase the Risk of Low BMD in Young Male Patients with Ankylosing Spondylitis  K.Y. Kang, Y.S. Hong, S.H. Park, J.H. Ju  ................................................................. 968

Pediatric Rheumatology

Dissecting the Heterogeneity of Macrophage Activation Syndrome Complicating Systemic JIA  F. Minoia, S. Davi, A. Horne, et al  ................................................................. 994
Participation in Leisure Activities among Canadian Children with Arthritis: Results from a National Representative Sample  S. Cavallo, A. Mainemier, B. Mazer, G. Chilingaryan, D. Ehrmann Feldman  ................................................................. 1002

Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)


Contents continued on page xx
Building Bridges between Researchers and Patient Research Partners: A Report from the GRAPPA 2014 Annual Meeting
M. de Wit, W. Campbell, A.M. Orbai, et al. 1021

The International Dermatology Outcome Measures Group: Update from the GRAPPA 2014 Annual Meeting
A.A. Levin, A.B. Gottlieb 1027

Dermatologists’ Management of PsA: A Report from the 2014 GRAPPA Meeting
W.H. Boehncke 1029

A Comprehensive Assessment Tool for Psoriasis — An Unmet Need: Report from the GRAPPA 2014 Annual Meeting
J.M. Cohen, A.A. Qureshi, J.F. Merola 1032

The Psoriasis Symptom Inventory: An Effective Patient-reported Outcome Measure of Psoriasis Severity
P.J. Mease 1034

Treat-to-target and Improving Outcomes in Psoriasis: A Report from the GRAPPA 2014 Annual Meeting
J. Takeshita, A.W. Armstrong, P.J. Mease, J.M. Gelfand 1037

Development of Simple Clinical Criteria for the Definition of Inflammatory Arthritis, Enthesitis, Dactylitis, and Spondylitis: A Report from the GRAPPA 2014 Annual Meeting

Utility in Clinical Trials of MRI for PsA: A Report from the GRAPPA 2014 Annual Meeting
M. Østergaard, D. Glinatsi, S.J. Pedersen, I.J. Sørensen 1044

Review of the Psoriatic Arthritis Working Group at OMERACT 12: A Report from the GRAPPA 2014 Annual Meeting
W. Tillet, L. Eder, N. Goel, et al 1048


Psoriasis and PsA Educational Initiatives: An Update from the 2014 GRAPPA Annual Meeting
K. Callis Duffin, P.J. Mease 1056

Correspondence
Extraarticular Manifestations of RA in Patients under Anti-TNF-α Treatment
C. Bachmeyer, C. Rein, S. Georgin-Lavialle 1059
Reply A.F. Negoescu, S.M. Abraham 1060
Anti-Jo1 Antibody in PM/DM Is Still Closely Associated with Lung rather than Joints L.H. Jearn, T.Y. Kim 1060
Reply J. Vencovský, M. Klein, H. Mann 1061
Primary or Secondary Synostosis: The Culmination of the Spondyloarthritis Form of Erosive Arthritis?
B.M. Rothschild 1062
Reply A.B. Maharaj, V. Chandran 1063

Letters
Anticyclic Citrullinated Peptide Antibodies in Patients with Rheumatic Diseases other than RA: Clinical or Pathogenic Significance? S. Caterbi, O. Bistoni, A. Alünno, E. Bartoloni, R. Gerli 1063
Infantile-onset LMNA-associated Muscular Dystrophy Mimicking Juvenile Idiopathic Inflammatory Myopathy
E. Moraitis, A.R. Foley, C.A. Pilkington, et al 1064

Meetings in Rheumatology xii